CSPC will receive an upfront $1.2 billion from AstraZeneca for access to eight programmes, AI molecular design capabilities, and the LiquidGel platform
rofitability showed strong momentum, with EBITDA rising 44.9% YoY to Rs. 8,697 million
On a proforma basis in Q3 FY26, revenues grew by 15% YoY to Rs. 2,366 Cr and operating EBITDA increased by 22% YoY to Rs. 503 Cr
The rating on senior secured notes issued by Biocon Biologics Global PLC was also upgraded to ‘BB+.’
The pioneering monoclonal antibody is for Essential Thrombocythemia (ET) and Polycythemia Vera (PV), rare chronic blood cancers with limited treatment options
The company reported Q3 total income of Rs. 1,005 million, marking a 10.2% increase year-on-year
Excluding Vacaville-related business, organic CER sales growth reached the low-teens with improved CORE EBITDA margins, in line with Lonza’s CDMO Organic Growth Model
The platform uses cutting-edge AI and automation to tackle the entire revenue cycle
The newly certified kits are designed for early detection and large-scale screening programs
The approval expands the drug’s existing COPD indication, making it the only single-inhaler triple therapy (SITT) available for both respiratory conditions in China
Subscribe To Our Newsletter & Stay Updated
